Looking to publish in Npj Precision Oncology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite Nownpj Precision Oncology is a Nature Portfolio journal in the npj Series, published in partnership with The Hormel Institute, featuring open access research, reviews, comments, and special collections in precision oncology.
Looking to publish in Npj Precision Oncology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowSubmission Instructions
Npj Precision Oncology accepts the following article types. Click on an article type to view submission instructions.
Article
Review
Brief Communication
Case Report
Recent Publications
Machine learning in automatic detection of chordoma signature, postoperative residuals, and prognosis of skull base chordomas
Daniela Stastna, Richard Mannion, Robert Macfarlane, Patrick Axon, Neil Donnelly, James R. Tysome, Daniele Borsetto, Ryan Chrenek, Kaasinath Balagurunath, Wenya Linda Bi, Carleton E. Corrales, Ossama Al-Mefty, Timothy Smith, Ari Ercole, Jonathan Coles
Molecular features unique to circulating tumor DNA enable the tumor-naïve liquid biopsy of glioblastoma
Hunter R. Underhill, Drew L. Sellers, Sabine Hellwig, Hediyeh Baradaran, Mary P. Bronner, Alun Thomas, Sarah Menacho, Christian J. Davidson, Rachna Malani, Andrew Farrell, Michael Karsy, David A. Nix, Yingqi Zhang, Laura A. Boatz, Joe Mendez, Lindsay Burt, Donald Cannon, Charlie S. Dean, Brion E. Harrison, Samuel Stevenson, Kinga Aitken, Stefan M. Pulst, Howard Colman, Randy L. Jensen
Author Correction: CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages
Silvia Pietrobono, Monica Bertolini, Veronica De Vita, Fabio Sabbadini, Federica Fazzini, Cristina Frusteri, Enza Scarlato, Domenico Mangiameli, Alberto Quinzii, Simona Casalino, Camilla Zecchetto, Valeria Merz, Davide Melisi
Targeting the CHD3 chromatin remodeler exploits a synthetic lethal vulnerability in dual SMARCA4/SMARCA2-deficient cancers via derepression of PARD3B
Mariko Takeuchi, Yoshie Okimoto, Makoto Fukushima, Harumi Hirano, Hideaki Ogiwara
Olverembatinib, a novel BCR-ABL tyrosine kinase inhibitor, exhibits anti-tumor activity and synergizes with gemcitabine in pancreatic ductal adenocarcinoma
Zengfei Xia, Runduan Lin, Fan Luo, Qiuyun Luo, Jing Yang, Shan Shi, Yan Li, Jiaxing Cao, Miaozhen Qiu, Lin Zhang, Wenlong Guan, Dajun Yang
Frequently asked questions
How long does it take to publish?
Median time from submission to first editorial decision is 18 days. Median time from submission to acceptance is 164 days.
Reformat to Npj Precision Oncology using Livewrite PremiumIs a cover letter required?
Authors should provide a cover letter including the affiliation and contact information for the corresponding author. The cover letter should briefly explain the context and importance of the work, why it is appropriate for the journal, and may include confidential information, related work, and suggested or excluded referees.
Reformat to Npj Precision Oncology using Livewrite PremiumWhat are the publication costs?
An article processing charge is required. Original Research: £3190.00 / $4290.00 / €3490.00. Brief Communication, Perspective, Review, Comment, Protocol, and Case Report: £1255.00 / $1780.00 / €1420.00. VAT or local taxes may apply.
Reformat to Npj Precision Oncology using Livewrite Premium